Reclaim the moments that move you
BREATHE THEM IN
WITH TYVASO FOR PH-ILD
TYVASO is approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
Hear how TYVASO helped Catherine be more active in her day-to-day life.
If you have been prescribed TYVASO for PH-ILD, you can talk to a Virtual Patient Educator* to learn more and receive support through the Archways program.
With the Co-Pay Assistance Card, eligible patients taking TYVASO who enroll may pay as little as a $5 co-pay per month and may receive up to $8000 in savings per year.